Homepage

Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries

Screening Compounds Building blocks

Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls

Company News & Media Contact us For suppliers Trends in discovery compounds

Homepage > Company > Media > Pharma News

Pharma News

Cancer drug helps treat tuberculosis by restoring leaky blood vessels

Cancer drug helps treat tuberculosis by restoring leaky blood vessels

Biomedical engineers have discovered an unlikely potential ally in the global fight against tuberculosis—an FDA-approved drug originally designed to treat cancer.

Could vitamin A derivative cure liver cancer?

Could vitamin A derivative cure liver cancer?

Researchers shed light on how a synthetic form of vitamin A could help to eradicate liver cancer.

Global study finds 44 genetic risk factors for major depression

Global study finds 44 genetic risk factors for major depression

LONDON (Reuters) - International scientists have identified 44 genetic variants that can increase the risk of developing major depression and found that all humans carry at least some of them.

New study shows life-saving outcomes using 3-D printing models for heart valve disease

New study shows life-saving outcomes using 3-D printing models for heart valve disease

SAN DIEGO, APRIL 26, 2018 - A new study examines the effectiveness of 3D printing technology and computer modeling to predict paravalvular leak (PVL) in patients undergoing transcatheter aorti...

Twice rejected by Lilly, Adocia mounts recovery with diabetes drug deal

Twice rejected by Lilly, Adocia mounts recovery with diabetes drug deal

Adocia has sold the Chinese rights to two diabetes prospects to Tonghua Dongbao Pharmaceuticals for $50 million (€41 million) upfront.

CTG Catapult opens its new unique cell and gene therapy plant in the U.K.

CTG Catapult opens its new unique cell and gene therapy plant in the U.K.

The government-funded Cell and Gene Therapy Catapult opened its $83.

Neurocrine presents positive analysis of Phase III Ingrezza data

Neurocrine presents positive analysis of Phase III Ingrezza data

Neurocrine Biosciences has presented a new analysis of data from the KINECT 3 Phase III trial of Ingrezza (valbenazine) showing improved outcomes for tardive dyskinesia (TD) patients.

Availability of orphan medicines varies between European countries

Availability of orphan medicines varies between European countries

There are differences in the availability of orphan medicines between different European countries, a new study from the University of Eastern Finland shows.

DNA. DNA is most commonly found in the well-known double helix shape, but new research shows it can take another form

DNA. DNA is most commonly found in the well-known double helix shape, but new research shows it can take another form

DNA. One of the most familiar shapes in science is DNA’s double helix structure.

FDA Approves Akynzeo for Injection

FDA Approves Akynzeo for Injection

Lugano, Switzerland April 20, 2018 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that the U.

FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis

FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis

INDIANAPOLIS, April 23, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE.

Otsuka’s JYNARQUE™ (tolvaptan) Approved by U.S. FDA as the First Treatment to Slow Kidney Function Decline in Adults at Risk of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Otsuka’s JYNARQUE™ (tolvaptan) Approved by U.S. FDA as the First Treatment to Slow Kidney Function Decline in Adults at Risk of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD)

TOKYO--(BUSINESS WIRE)--Otsuka Pharmaceutical Co.

444 445 446 447448449 450 451 452